

## Supplementary Materials

### Terpenoids from the seeds of *Toona sinensis* and their ability to attenuate high glucose-induced oxidative stress and inflammation in rat glomerular mesangial cells

Ying Chen <sup>†</sup>, Hong Gao <sup>†</sup>, Xiaoxiao Liu <sup>†</sup>, Jinyi Zhou, Yijin Jiang, Feng Wang, Rongshen Wang <sup>\*</sup>, Wanzhong Li <sup>\*</sup>

*School of Pharmacy, Weifang Medical University, Weifang 261053, P. R. China*

**Abstract:** *Toona sinensis* (A. Juss.) Roem is an edible medicinal plant that belongs to the genus *Toona* in the Meliaceae family. It has been confirmed to display a wide variety of biological activities. During our continuous search for active constituents from the seeds of *T. sinensis*, 2 new acyclic diterpenoids (**1–2**), together with 5 known limonoid-type triterpenoids (**3–7**), 5 known apotirucallane-type triterpenoids (**8–12**), and 3 known cycloartane-type triterpenoids (**13–15**), were isolated and characterized. Their structures were identified based on extensive spectroscopic experiments including nuclear magnetic resonance (NMR), high-resolution electrospray ionisation mass spectra (HR-ESI-MS), and electronic circular dichroism (ECD), as well as the comparison with those reported in the literature. We compared these findings to those reported in the literature. Compounds **5**, **8**, and **13–14** were isolated from the genus *Toona*, and compounds **11** and **15** were obtained from *T. sinensis* for the first time. The antidiabetic nephropathy effects of isolated compounds against high glucose-induced oxidative stress and inflammation in rat glomerular mesangial cells (GMCs) were assessed *in vitro*. The results showed that new compounds **1** and **2** could significantly increase the levels of Nrf-2/HO-1 and reduce the levels of NF- $\kappa$ B, TNF- $\alpha$ , and IL-6 at concentrations of 30  $\mu$ M. These results suggest that compounds **1** and **2** might prevent the occurrence and development of diabetic nephropathy (DN) and facilitate the research and development of new antioxidant and anti-inflammatory drugs suitable for the prevention and treatment of DN.

**Keywords:** *Toona sinensis* (A. Juss.) Roem; acyclic diterpenoids; rat glomerular mesangial cells; oxidative stress; inflammation

## Computational methods

### 1. Conformational analysis and structure optimization

The conformers of each configuration that were obtained with conformational analysis were then optimized with the software package Gaussian 09 at the M062X/6-31G(d) level. Room-temperature equilibrium populations were calculated according to Boltzmann distribution law (eq. S1). The energies and populations of dominative conformers were obtained.

$$\frac{N_i}{N} = \frac{g_i e^{-\frac{E_i}{k_B T}}}{\sum g_i e^{-\frac{E_i}{k_B T}}} \quad (\text{S1})$$

where  $N_i$  is the number of conformer  $i$  with energy  $E_i$  and degeneracy  $g_i$  at temperature  $T$ , and  $k_B$  is Boltzmann constant.

### 2. NMR calculation

NMR calculations were carried out by Gaussian 09 following the protocol adapted from Lodewyk *et al.* [1]. The theoretical calculation of NMR was conducted using the Gauge-Including Atomic Orbitals (GIAO) method at mPW1PW91/6-31G(d) by the SMD model. Finally, the calculated NMR chemical shift values were averaged according to Boltzmann distribution for each conformer and fitting to the experimental values by linear regression. DP4+ probability analysis was performed according to the reported methods [2].

## References

1. Lodewyk, M.W., Siebert, M.R., Tantillo, D.J. Computational prediction of  $^1\text{H}$  and  $^{13}\text{C}$  chemical shifts: a useful tool for natural product, mechanistic, and synthetic organic chemistry. *Chem. Rev.* **2012**, *112*, 1839–1862.
2. Grimblat, N., Zanardi, M.M., Sarotti, A.M. Beyond DP4: an improved probability for the stereochemical assignment of isomeric compounds using quantum chemical calculations of NMR shifts. *J. Org. Chem.* **2015**, *80*, 12526–12534.

## List of Figures

Figure S1. The effects of compounds **1–15** (80  $\mu$ M) on cells viability of GMCs were tested by MTT assay. Values are expressed as mean  $\pm$  SD of three independent experiments, with  $^{**}P < 0.01$  relative to the NG.

Figure S2.  $^1\text{H}$  NMR spectrum of compound **1** in  $\text{CDCl}_3$  (600 MHz)

Figure S3.  $^{13}\text{C}$  NMR spectrum of compound **1** in  $\text{CDCl}_3$  (150 MHz)

Figure S4. DEPT 135° spectrum of compound **1** in  $\text{CDCl}_3$

Figure S5.  $^1\text{H}$ – $^1\text{H}$  COSY spectrum of compound **1** in  $\text{CDCl}_3$

Figure S6. HMQC spectrum of compound **1** in  $\text{CDCl}_3$

Figure S7. HMBC spectrum of compound **1** in  $\text{CDCl}_3$

Figure S8. NOESY spectrum of compound **1** in  $\text{CDCl}_3$

Figure S9. HR-ESI-MS of compound **1**

Figure S10.  $^1\text{H}$  NMR spectrum of compound **2** in  $\text{CDCl}_3$  (600 MHz)

Figure S11.  $^{13}\text{C}$  NMR spectrum of compound **2** in  $\text{CDCl}_3$  (150 MHz)

Figure S12. DEPT 135° spectrum of compound **2** in  $\text{CDCl}_3$

Figure S13.  $^1\text{H}$ – $^1\text{H}$  COSY spectrum of compound **2** in  $\text{CDCl}_3$

Figure S14. HMQC spectrum of compound **2** in  $\text{CDCl}_3$

Figure S15. HMBC spectrum of compound **2** in  $\text{CDCl}_3$

Figure S16. NOESY spectrum of compound **2** in  $\text{CDCl}_3$

Figure S17. HR-ESI-MS of compound **2**

Figure S18. Chemical structure of the calculated configurations.

Table S1. Statistics of ordinary least squares (OLS) linear regression of experimental and computed  $^{13}\text{C}$ -NMR chemical shifts.




Figure S1. The effects of compounds **1–15** (80  $\mu$ M) on cells viability of GMCs were tested by MTT assay. Values are expressed as mean  $\pm$  SD of three independent experiments, with \*\* $P < 0.01$  relative to the NG.




Figure S2.  $^1\text{H}$  NMR spectrum of compound **1** in  $\text{CDCl}_3$  (600 MHz)




Figure S3.  $^{13}\text{C}$  NMR spectrum of compound **1** in  $\text{CDCl}_3$  (150 MHz)




Figure S4. DEPT  $135^\circ$  spectrum of compound **1** in  $\text{CDCl}_3$




Figure S5.  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound **1** in  $\text{CDCl}_3$




Figure S6. HMQC spectrum of compound **1** in  $\text{CDCl}_3$




Figure S7. HMBC spectrum of compound **1** in CDCl<sub>3</sub>




Figure S8. NOESY spectrum of compound **1** in CDCl<sub>3</sub>




Figure S9. HR-ESI-MS of compound **1**




Figure S10.  $^1\text{H}$  NMR spectrum of compound **2** in  $\text{CDCl}_3$  (600 MHz)




Figure S11. <sup>13</sup>C NMR spectrum of compound **2** in CDCl<sub>3</sub> (150 MHz)




Figure S12. DEPT 135° spectrum of compound **2** in CDCl<sub>3</sub>




Figure S13.  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound **2** in  $\text{CDCl}_3$




Figure S14. HMQC spectrum of compound **2** in  $\text{CDCl}_3$




Figure S15. HMBC spectrum of compound **2** in CDCl<sub>3</sub>




Figure S16. NOESY spectrum of compound **2** in CDCl<sub>3</sub>




Figure S17. HR-ESI-MS of compound **2**




Figure S18. Chemical structure of the calculated configurations.

Table S1. Statistics of ordinary least squares (OLS) linear regression of experimental and computed  $^{13}\text{C}$ -NMR chemical shifts.

Configuration	DP4+ probability (%)	$R^2$	RMSE
<b>1a</b>	100	0.9924	4.28
<b>1b</b>	0	0.9905	4.63
<b>2a</b>	93.26	0.9951	3.73
<b>2b</b>	6.74	0.9958	3.53